SAB Biotherapeutics Starts GMP Manufacturing, Expands Plasma Network 30% in Q1
SABS•In its Q1 2026 earnings call SAB Biotherapeutics announced initiation of GMP manufacturing for its lead hyperimmune therapeutic and a 30% expansion of its plasma collection network to support pipeline scalability. Management also spotlighted progress across two preclinical antibody programs targeting emerging viral pathogens.
1. Q1 Earnings Call Overview
SAB Biotherapeutics opened its Q1 2026 call by outlining key operational milestones, notably the transition of its lead hyperimmune candidate into GMP production to meet anticipated clinical and commercial demand.
2. Manufacturing and Network Expansion
The company expanded its animal plasma collection network by 30%, enhancing raw material availability for antibody therapies and strengthening supply chain robustness for future scale-up.
3. Preclinical Pipeline Progress
Executives provided updates on two antibody programs in preclinical stages targeting emerging viral threats, confirming in vivo efficacy studies and outlining plans for IND filings later this year.
4. Strategic Partnerships Outlook
Management noted ongoing negotiations for strategic collaborations aimed at co-development and commercialization, designed to broaden SAB’s market reach and accelerate late-stage program funding.
